The Syneos Health Podcast | CNS Summit 2025 Series
Now in its second season, this exclusive podcast series—produced in collaboration with CNS Summit—features biopharma leaders sharing bold ideas, breakthrough innovations and what it takes to move smarter and faster for patients.
Each episode explores the mindset and momentum behind today’s most transformative strategies. Listen in to stay ahead of what’s next in life sciences.
Scroll down to explore all episodes or tune in wherever you get your podcasts.
The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.
Want to be notified when new episodes are released?
Episode 1: Can Psychedelics Reshape Psychiatry? A Conversation with Kabir Nath, CEO, Compass Pathways
Compass Pathways CEO Kabir Nath joins host, Dr. Alex Wise, Global Head of Neuroscience at Syneos Health, to discuss the clinical promise of psychedelics and what’s next for psychiatric innovation.
What you’ll learn:
- What’s driving the momentum behind psilocybin therapy
- Why investor confidence is growing in mental health biotech
- How biopharma can better communicate the value of innovation
- Kabir’s message to next-gen leaders in science and strategy


Episode 2: Balanced Disruption in Neurology, A Conversation with Merz Therapeutics CEO Stefan König
How is a mid-sized, family-owned company scaling with impact in specialty neurology? Stefan König, CEO of Merz Therapeutics joins guest host Andy Moniz, VP of Therapeutic Strategy and Innovation at Syneos Health at the 2025 CNS Summit. Together, they explore what it takes to lead through volatility, invest globally and grow with intention, all while upholding culture and delivering with purpose.
In this episode:
- How Merz is leveraging global capital to expand its neurology pipeline
- What today’s market volatility reveals about opportunity
- Why “balanced disruption” matters for scaling innovation
Listen here or find this episode wherever you get your podcasts.




